---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-114730"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:40:43.098061+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics prices $85M public offering of common stock and pre-funded warrants

## Summary
- Priced 19.3M shares at $3.85/share and pre-funded warrants for 2.75M shares at $3.8499 each.
- Gross proceeds expected ~$85M; net proceeds ~$69.7M ($81.7M if over-allotment option exercised).
- Proceeds to fund clinical development of SAB-142 (anti-thymocyte immunoglobulin) for type 1 diabetes.
- Offering led by Jefferies, UBS, Citigroup, Barclays; expected to close March 19, 2026.
- 30-day over-allotment option for additional 3.31M shares.

## SEC filing metadata
- accession: 0001193125-26-114730
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000119312526114730/0001193125-26-114730-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000119312526114730/sabs-20260317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-114730
- JSON: https://secwatch.observer/filing/0001193125-26-114730.json
- Plain text: https://secwatch.observer/filing/0001193125-26-114730.txt

## Key facts
- Material Agreements
  SAB Biotherapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, UBS Securities LLC, Citigroup Capital Markets, Inc. and Barclays Capital Inc. valued at underwritten offering of common stock and pre-funded warrants (effective 2026-03-17).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Jefferies LLC, UBS Securities LLC, Citigroup Capital Markets, Inc. and Barclays Capital Inc.
  - Value: underwritten offering of common stock and pre-funded warrants
  - Effective: 2026-03-17
  source text: On March 17, 2026, SAB Biotherapeutics, Inc. (the “Company” or “SAB”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, UBS Securities LLC, Citigroup Capital Markets, Inc. and Barclays Capital Inc. (collectively, the “Representatives”) as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten offering (the “Offering”) of (i) 19,324,677 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), at a price to the public of $3.85 per Firm Share, and (ii) pre-funded warrants to purchase up to 2,753,246 shares of Common Stock (the “Pre-Funded Warrants”), and such shares issuable upon the exercise of the Pre-Funded Warrants (the “Warrant Shares”), at a price to the public of $3.8499 per Pre-Funded Warrant, which represents the per share public offering price for the Firm Shares less the $0.0001 per share exercise price for each such Pre-Funded Warr
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000119312526114730/0001193125-26-114730-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.